Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (NYSE American: AIM) entered definitive agreements for a registered direct offering of 7,519,351 common shares (or equivalents) at $0.325 per share, for expected gross proceeds of about $2.4 million before fees.
Concurrent with this, AIM will privately issue Series I warrants to purchase up to 15,038,702 shares at $0.325, exercisable for five years subject to stockholder approval. Closing is expected around May 21, 2026. According to AIM ImmunoTech, net proceeds will fund clinical drug supply manufacturing, planned Phase 3 trial activities, and working capital.
AIM ImmunoTech (NYSE American:AIM) reported a significant rise in stockholder equity and an extension of its key promissory note to June 30, 2027.
Equity reached about $2.1 million as of March 31, 2026, up roughly $11.9 million from a prior deficit, supporting its pancreatic cancer development strategy.
AIM ImmunoTech (NYSE American: AIM) released a Virtual Investor KOL segment highlighting Ampligen (rintatolimod) data in late-stage pancreatic cancer. Professor Casper H.J. van Eijck and CEO Thomas K. Equels discuss mechanism, clinical results, strategy and regulatory plans.
Data from an Erasmus MC Named Patient Program showed progression-free survival of 12.6 vs 8.6 months and overall survival of 19.7 vs 12.5 months versus historical controls, with larger gains in selected biomarker subgroups. Ampligen is also being studied in the Phase 2 DURIPANC trial with AstraZeneca’s Imfinzi, with a mid-year 2026 update and enrollment completion expected in June 2026. Multiple peer-reviewed publications describe Ampligen’s pancreatic cancer research.
AIM ImmunoTech (NYSEAM:AIM) announced that holders will exercise existing Class A–F warrants to buy up to 8,719,928 common shares at $0.48 per share for gross proceeds of approximately $4.2 million, before fees. The company plans to use net proceeds for working capital and general corporate purposes.
In exchange, exercising holders will receive private Replacement Warrants exercisable, upon stockholder approval, into up to 17,439,856 shares at $0.60 per share for five years. The offering is expected to close on or about May 8, 2026, subject to customary closing conditions.
AIM ImmunoTech (NYSE American: AIM) reported final primary endpoint results from a UPMC Phase 2 trial combining Ampligen (rintatolimod) with pembrolizumab and cisplatin in recurrent ovarian cancer. Topline: 50% ORR, 21% complete responses, 79% clinical benefit rate, median OS 32.5 months, durable responses >70 months, and no Grade 4–5 toxicities. Additional secondary endpoint data collection is expected to complete in January 2027.
AIM ImmunoTech (NYSE American: AIM) disclosed that its audited consolidated financial statements for the year ended December 31, 2025 include an independent auditor's going concern emphasis of matter. This disclosure is required by NYSE American Section 610(b) and does not amend prior filings.
The company said management remains confident in its ability to raise funds and highlighted positive progress in the Phase 2 DURIPANC study of Ampligen plus durvalumab for metastatic pancreatic cancer; the next DURIPANC update is expected in June 2026.
AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell Event on Thursday, April 16, 2026 at 4:00 PM ET. CEO Thomas K. Equels will give a corporate overview and business outlook and take live questions from investors.
A live video webcast will be available on the company Events page and a replay will be posted two hours after the presentation and accessible for 90 days.
AIM (NYSE: AIM) announced final approval of a Japanese patent covering Ampligen (rintatolimod) combined with checkpoint inhibitors for cancer treatment, with claims that include pancreatic cancer.
The patent was granted in September 2025 after a 6-month opposition period and expires December 20, 2039. AIM also holds related patents in the U.S. (expires August 9, 2039) and the Netherlands (expires December 19, 2039) and plans to pursue Japanese Orphan Drug Designation for Ampligen in pancreatic cancer. The company already holds U.S. and EU orphan designations.
AIM ImmunoTech (NYSE:AIM) announced the closing of its rights offering on March 6, 2026, which generated approximately $1.8 million in total subscriptions. Each purchased Unit was priced at $1,000 and consisted of one share of Series G convertible preferred stock and 2,000 Class G warrants.
The offering used a Form S-1 registration (No. 333-292085) declared effective by the SEC on February 10, 2026, with a prospectus supplement filed February 27, 2026. Maxim Group acted as dealer-manager.
AIM ImmunoTech (NYSE American: AIM) announced preliminary results of a rights offering that expired March 3, 2026, estimating aggregate subscriptions of approximately $1.8 million.
The offering sold Units at $1,000 per Unit (one Series G convertible preferred share plus 2,000 Class G warrants). Closing is anticipated on or about March 6, 2026, subject to customary conditions.